. Author manuscript; available in PMC: 2012 Jul 1.

Published in final edited form as: Brain Behav Immun. 2010 Dec 10;25(5):830–839. doi: 10.1016/j.bbi.2010.12.002

Table 4.

Mean Fluorescent Intensity of CD56+ Lymphocytes at Diagnosis (P1) and After Completion of Cancer Treatment (P2)

Histone Residue	Mean Fluorescent Intensity (MFI)
Histone Residue	P1	P2	t	df	p

CD56+	(mean ± SEM) [95% CI]
H4-K8 Ac	2,871 ±343	4,662 ± 579	2.660	28	0.013
	[1.4–29.7]
H4-K12 Ac	2,286 ± 325	4,054 ± 576	2.673	29	0.012
	[412–3,124]
H3-S10 PO4	1,485 ± 360	1,885 ± 597	1.788	30	0.084
	[−86–1,305]

Isotype control antibody exhibited a mean fluorescent intensity (MFI) < 150.

P1= after surgery but before radiation therapy, P2 = 2 months after the completion of radiation therapy.

H4-K8 Ac, N=30, H4-K12 Ac, N= 31, H3-S10 P04, N=32.